Abstract: A machine learning accelerator (MLA) implemented on a semiconductor die includes a computing mesh of interconnected compute elements that includes storage elements (SEs) and processing elements (PEs). The compute elements execute a program of instructions to implement a machine learning network according to a static schedule for execution of the instructions. The instructions include data transfer instructions and compute instructions. The MLA includes a memory interface to off-chip memory. The MLA fetches instructions for the PEs from the off-chip memory, and the MLA transfers data between the SEs and the off-chip memory. A sync detector determines, for each compute element, whether sufficient data and instructions are available for continued operation of the compute element according to the static schedule. It generates a sync request if sufficient data and/or instructions are not available. A sync controller suspends operation of the computing mesh in response to the sync request.

Abstract: Provided are antibiotic conjugate compounds of formula (I) and pharmaceutical compositions thereof. Also provided are methods of treating treat bacterial infection, including infections caused by Gram-negative bacteria, by administering compounds of formula (I).

Abstract: The following invention deals with the design, preparation, evaluation, and use of carbapenem antibiotics with improved activity, relative to current commercially available carbapenem antibiotics, against infections involving multidrug resistant, carbapenemase-producing Acinetobacter baumannii. The new carbapenem antibiotics are demonstrated to possess not only inherent antimicrobial activity, but also the ability to inhibit OXA-23, the most commonly produced serine carbapenemase in this species. This unusual carbapenemase-inhibitory activity also indicates that the compounds may be used synergistically, in combination with current commercial carbapenem antibiotics, to inhibit key class D carbapenemases, such as OXA-23. Additionally, one of the newly reported carbapenems is active against metallo-beta-lactamase producing A. baumannii. This is the first report of a metallo-beta-lactamase stable carbapenem antibiotic.